Affimed Therapeutics Files $75M IPO

July 01, 2014

Share:

Affimed Therapeutics

Affimed Therapeutics has filed to list on the NASDAQ under the symbol AFMD, planning to raise $75 million (€55 million) in its IPO. At the time of filing, the Germany-based company had raised close to $89 million (€65 million) from investors including OrbiMed Advisors, Aeris Capital, BioMedPartners, Novo Nordisk and Life Sciences Partners. Affimed is a developer of immunotherapy antibodies that treat cancer by establishing a bridge between immune and tumor cells that trigger a signal cascade resulting in destruction of the cancer cells.